Blocking hWARS Receptors to Prevent Enterovirus A71 Cell Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for enterovirus infections, particularly those caused by enterovirus 71, lack specificity and effectiveness, with existing methods either targeting broad microRNAs or relying on variable traditional medicines and antibodies with reduced affinity, failing to adequately address the severe complications associated with EV-A71 infections.
Innovation Solution
The development of compounds and methods that reduce the accessibility of the human tryptophanyl-tRNA synthetase (hWARS) protein on the cell surface to enteroviruses, using hWARS blocking antibodies, small molecules, or soluble hWARS analogs to block virus binding, or modifying the expression and activity of pro-inflammatory peptides like IFNγ to alter the balance between T-helper1 and T-helper2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional Chinese medicines or broad-spectrum antisense oligonucleotides are used for treatment, then a wide range of viruses may be addressed, but specificity for EV-A71 is lost and severe complications are not adequately prevented
Solution Approach 1:
The patent uses hWARS blocking antibodies as intermediary molecules that specifically bind to the hWARS receptor on host cells, preventing EV-A71 from attaching and entering the cell. This intermediary approach provides EV-A71-specific protection without requiring direct viral antigen recognition, thereby achieving high specificity while maintaining broad applicability across different EV-A71 strains
Solution Approach 2:
The patent modifies the therapeutic approach by changing from direct viral targeting (antibodies against viral antigens) to host receptor blocking (antibodies against hWARS). This parameter change in the target object allows for consistent specificity against EV-A71 regardless of viral strain variations, while the single target approach simplifies manufacturing precision requirements
2Manufacturing precision
If virus-directed therapeutic antibodies are used, then specific EV-A71 neutralization is achieved, but dosage determination becomes complex due to varying viral loads in different infection phases
Solution Approach 1:
By using hWARS blocking antibodies as intermediaries that target the host cell receptor rather than the virus directly, the patent creates a standardized therapeutic approach where dosage can be determined based on receptor blocking requirements rather than viral load measurements. This intermediary mechanism simplifies dosage determination while maintaining EV-A71 specificity
Solution Approach 2:
Instead of measuring viral load to determine antibody dosage (traditional approach), the patent inverts the logic by using fixed dosing based on host receptor blocking requirements. This inversion eliminates the need for complex viral load staging and simplifies the dosing regimen while maintaining therapeutic effectiveness
3Measurement precision
If monoclonal antibodies with high affinity are developed, then diagnostic specificity is improved, but treatment affinity is reduced when humanized
Solution Approach 1:
The patent uses hWARS blocking antibodies as intermediaries that bind to the host receptor rather than viral antigens. This approach maintains high binding affinity in humanized forms because the antibodies target conserved host protein epitopes rather than variable viral antigens, thereby preserving treatment efficacy while enabling humanization for therapeutic use
Solution Approach 2:
The patent changes the target from viral antigens (variable, leading to affinity loss upon humanization) to host receptor hWARS (conserved, maintaining affinity after humanization). This parameter change in the target object allows humanized antibodies to maintain high binding affinity while achieving the necessary specificity for EV-A71 treatment
Data Source
AI summary
Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.